Clinical Trial Update: Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions [Phase 2]

View source ↗

Summary

Phase 2 trial investigating E7 T cell receptor T cells for vulvar high-grade squamous intraepithelial lesions (HSIL) by NCI; study terminated with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Intraepithelial Lesions of the Vulva
• Vulvar Cancer
• Vulvar High-grade Squamous Intraepithelial Lesions

Drugs mentioned

• E7 T cell receptor T cells (E7 TCR-T cells)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Squamous Lntraepithelial Lesions of Vulva, Neoplasms, Squamous Cell | Phase 2 | Status: TERMINATED | Results posted: 2021-03-18